Inotiv Inc (NOTV) fair value: what the stock is really worth
As of Jun 15, 2026: fair value of Inotiv Inc $0.03, price $0.04, upside -16.0%, quality 24 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Inotiv Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range $0.0360 – $57.88 · fair‑value band $0.0266 – $0.0302 · the $0.0360 price screens above the $0.0302 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 13, 2026.
Follow Inotiv in your weekly email
Every Wednesday you see whether Inotiv is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS).
Show more
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana. On June 3, 2026, Inotiv, Inc. along with its affiliates filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
Stock analysis
Inotiv Inc (NOTV) currently trades at $0.0360, while our model-based Fair Value estimate is $0.0302, 16.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 3 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.0266 (bear) to $0.0302 (bull), the price of $0.0360 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Inotiv Inc reported revenue of $513M in FY2025 versus $89.6M in FY2021, a compound +54.7%/yr. Reported net income was −$68.6M in FY2025.
Key figures
Market cap $2.8M · EPS (TTM) $−2.48 · Net margin −13.4% · Return on equity −74.1% · Return on assets (EBIT) −5.4% · Operating margin −16.0% · Revenue (TTM) $507M · Revenue growth (YoY) −5.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).
What moves the price
The share trades about 98% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −16%, NOTV screens richer than that median.
Fair Value models
Bear $0.0266Fair Value $0.0302Bull $0.0302
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+4.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+53.4%
Start year 2020 (pandemic). Over 10 years: +36.6% a year
Revenue growth 28 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5.1% (2020) → −6.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 134 stocks
Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score24 · Bottom 25%
Fair Value upside−16.1% · Above median
Profitability
Return on assets−4.0% · Bottom 25%
Net margin (TTM)−17.1% · Bottom 25%
Operating margin (TTM)−16.0% · Bottom 25%
Growth and dividend
Revenue growth−5.4% · Bottom 25%
Balance sheet
Debt / equity2.87× · Highest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Inotiv Inc Fair Value". https://www.fairvalue-calculator.com/stock/NOTV
Frequently asked questions
Is Inotiv Inc (NOTV) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $0.0302 versus the last price from Jun 15, 2026 of $0.0360, about −16% upside (overvalued).
What is the fair value of NOTV?
Our model-based fair value for Inotiv Inc is $0.0302 (as of Sep 13, 2026), built from audited fundamentals. Last price (from Jun 15, 2026): $0.0360.
What is the quality score of NOTV?
Inotiv Inc has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Inotiv Inc (NOTV)?
Our model-based price target is the fair value of $0.0302 (as of Sep 13, 2026) from 2 valuation models. Cautious scenario $0.0266, optimistic scenario $0.0302. It is a calculation from audited fundamentals, not an analyst target.
What is the Inotiv Inc stock forecast for 2026?
Our models put fair value at $0.0302, about −16% upside versus the last price from Jun 15, 2026 of $0.0360 (overvalued). Cautious scenario $0.0266, optimistic scenario $0.0302. The calculation is refreshed regularly with new filings.
What is the revenue of Inotiv Inc (NOTV)?
Inotiv Inc reported trailing-twelve-month revenue of about $507M (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Inotiv Inc (NOTV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Inotiv Inc it is $0.0302 per share (as of Sep 13, 2026), against a price of $0.0360. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Inotiv Inc stock overvalued or undervalued in 2026?
As of Sep 13, 2026, NOTV trades above its calculated fair value: price $0.0360, fair value $0.0302, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NOTV?
No. The price is what the market pays today ($0.0360); the fair value is what the company's own numbers justify ($0.0302). For Inotiv Inc the two are $0.0058 per share apart. That gap is exactly why we show both numbers side by side.
How much is Inotiv Inc worth?
The market values Inotiv Inc at about $2.8M (market capitalisation, as of Sep 13, 2026). Per share that is $0.0360; our models calculate a fair value of $0.0302 per share.
What do the bullish and bearish scenarios say about NOTV?
Our models span a range for Inotiv Inc: cautious scenario $0.0266, base $0.0302, optimistic $0.0302 per share (as of Sep 13, 2026, price $0.0360). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Inotiv Inc (NOTV)?
Balance-sheet figures for Inotiv Inc (as of Sep 13, 2026): return on equity −74.1%, debt of 2.87 per unit of equity. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is NOTV from its 52-week high?
Inotiv Inc trades at $0.0360, about 98% below its 52-week high of $2.36 and at the low of $0.0360 (as of Jun 15, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0302 is for.
Which stocks are comparable to Inotiv Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Inotiv Inc stock attractive at the current price?
The data as of Sep 13, 2026: price $0.0360, calculated fair value $0.0302 (−16%), Quality Score 24/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NOTV calculated?
We run Inotiv Inc through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0302, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Inotiv Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Inotiv Inc (NOTV)?
The latest price we hold is from Jun 15, 2026 and stands at $0.0360. Our model-based fair value is $0.0302, about −16% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Inotiv Inc right now?
The price sits above even our optimistic bull case ($0.0302). The favourable scenario is already priced in. Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band ($0.0266 to $0.0302), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Inotiv Inc
How large is the market capitalisation of Inotiv Inc (NOTV)?
The market capitalisation of Inotiv Inc is $2.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Inotiv Inc (NOTV)?
Earnings per share at Inotiv Inc are $−2.48. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Inotiv Inc (NOTV)?
The net margin of Inotiv Inc is −13.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Inotiv Inc (NOTV)?
The return on equity (ROE) of Inotiv Inc is −74.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Inotiv Inc (NOTV)?
On an EBIT basis the return on assets of Inotiv Inc is −5.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Inotiv Inc (NOTV)?
The operating margin of Inotiv Inc is −16.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Inotiv Inc (NOTV)?
Revenue at Inotiv Inc is growing −5.4% versus a year earlier (3y avg −2.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Inotiv Inc (NOTV) generate?
The free cash flow of Inotiv Inc is −$27.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Inotiv Inc (NOTV) carry?
The net debt of Inotiv Inc is $482M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Inotiv Inc in the live analysis
One click puts Inotiv Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 13, 2026